Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- Leukemia
- Interventions
- Biological: recombinant 70-kD heat-shock protein
- Registration Number
- NCT00030303
- Lead Sponsor
- UConn Health
- Brief Summary
RATIONALE: Vaccines made from a person's white blood cells may make the body build an immune response to kill cancer cells.
PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have chronic myelogenous leukemia.
- Detailed Description
OBJECTIVES:
* Determine the feasibility of vaccination with autologous heat shock protein 70 in patients with chronic phase chronic myelogenous leukemia.
* Determine the toxicity of this vaccination in these patients.
OUTLINE: Patients undergo leukapheresis to obtain peripheral mononuclear cells (PMNCs). Heat shock protein 70 (HSP70) is derived from the autologous PMNCs. Patients receive HSP70 intradermally once weekly for 8 weeks.
Patients are followed for 2 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description vaccine recombinant 70-kD heat-shock protein recombinant 70-kD heat-shock protein
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Connecticut Health Center
🇺🇸Farmington, Connecticut, United States